Studies of patients failing second-line antiretroviral therapy (ART) in resource-limited settings (RLS) are few. Evidence suggests most patients who appear to be virologically failing do so not due to drug resistance but to poor adherence, which, if properly addressed, could allow continued use of less expensive first- and second-line regimens. Drug resistant mutations (DRMs) were characterized among patients virologically failing second-line ART in Rwanda.
Methods
A total of 128 adult patients receiving second-line ART for at least 6 months were invited to participate; 74 agreed and had HIV-1 viral load (VL) measured. Resistance genotypes were conducted in patients with virological failure (VF; that is, VL ≥1,000 copies/ml).
Results
In total, 35 patients met the criteria for VF. The median time on lopinavir/ritonavir-based second-line ART was 2.7 years. Of 30 successful resistance genotype analyses, 13 (43%) had ≥1 nucleoside reverse transcriptase inhibitor (NRTI) mutation, 18 (60%) had at least 1 non-NRTI mutation and 5 (17%) had at least 1 major protease inhibitor mutation. Eleven (37%) had virus without significant mutations that would be fully sensitive to first-line ART; 12 (40%) had DRM to first-line ART but sensitive to second-line ART. Only 7 patients (23%) demonstrated a DRM profile requiring third-line ART.
Conclusions
Among 30 genotyped samples of patients with VF on second-line ART, more than one-third had no significant DRMs, implicating poor adherence as the primary cause of VF. The majority of patients (77%) would not have required third-line ART. These findings reinforce the need for intensive adherence assessment and counselling for patients who appear to be failing second-line ART in RLS.
References
1.
NsanzimanaS., RutonH., LowranceD.W.Cell phone-based and internet-based monitoring and evaluation of the National Antiretroviral Treatment Program during rapid scale-up in Rwanda: TRACnet, 2004-2010.J Acquir Immune Defic Syndr2012; 59: e17–e23.
2.
Art-Linc of IeDEA Study Group, KeiserO., TweyaH.Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring.AIDS2009; 23: 1867–1874.
3.
SungkanuparphS., WinM.M., KiertiburanakulS., PhonratB., Maek-a-nantawatW.HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting.Int J STD AIDS2012; 23: 316–318.
4.
Osinusi-AdekanmbiO., StaffordK., UkpakaA.Long-term outcome of second-line antiretroviral therapy in resource-limited settings.J Int Assoc Provid AIDS Care2014; 13: 366–371.
HosseinipourM.C., GuptaR.K., Van ZylG., EronJ.J., NachegaJ.B.Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.J Infect Dis2013; 207Suppl 2: S49–S56.
7.
AjoseO., MookerjeeS., MillsE.J., BoulleA., FordN.Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis.AIDS2012; 26: 929–938.
8.
MurphyR.A., SunpathH., CastillaC.Second-line antiretroviral therapy: long-term outcomes in South Africa.J Acquir Immune Defic Syndr2012; 61: 158–163.
9.
SchoffelenA.F., WensingA.M., TempelmanH.A., GeelenS.P., HoepelmanA.I., BarthR.E.Sustained virological response on second-line antiretroviral therapy following virological failure in HIV-infected patients in rural South Africa.PLoS ONE2013; 8: e58526.
10.
El-KhatibZ., EkstromA.M., LedwabaJ.Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.AIDS2010; 24: 1679–1687.
11.
MaigaA.I., FofanaD.B., CisseM.Characterization of HIV-1 antiretroviral drug resistance after second-line treatment failure in Mali, a limited-resources setting.J Antimicrob Chemother2012; 67: 2943–2948.
12.
SaravananS., VidyaM., BalakrishnanP.Viremia and HIV-1 drug resistance mutations among patients receiving second-line highly active antiretroviral therapy in Chennai, Southern India.Clin Infect Dis2012; 54: 995–1000.
HosseinipourM.C., van OosterhoutJ.J., WeigelR.The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.AIDS2009; 23: 1127–1134.
15.
SungkanuparphS., ManosuthiW., KiertiburanakulS., PiyavongB., ChumpathatN., ChantratitaW.Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.Clin Infect Dis2007; 44: 447–452.
16.
Cozzi-LepriA., PhillipsA.N., Martinez-PicadoJ.Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.J Infect Dis2009; 200: 687–697.
17.
HamersR.L., SigaloffK.C., WensingA.M.Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.Clin Infect Dis2012; 54: 1660–1669.
18.
HansonD.L., Adje-ToureC., Talla-NzussouoN.HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Cote d'Ivoire.AIDS Res Hum Retroviruses2009; 25: 489–495.
19.
LorenzanaS.B., HughesM.D., GrinsztejnB.Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.AIDS2012; 26: 1083–1093.
